Bibliography
- Mahler HC , FriessW, GrauschopfU, KieseS. Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci. 98(9), 2909–2934 (2009).
- Koren E , De Groot AS, Jawa Vet al. Clinical validation of the ‘in silico ’ prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 124(1), 26–32 (2007).
- Szebeni J . Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology216(2–3), 106–121 (2005).
- Braun A , KweeL, LabowMA, AlsenzJ. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon a in normal and transgenic mice. Pharm. Res. 14(10), 1472–1478 (1997).
- Shankar G , PendleyC, SteinK. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25(5), 555–561 (2007).
- Ponce R , AbadL, AmaravadiLet al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 54(2), 164–182 (2009).
- Shankar G , DevanarayanV, AmaravadiLet al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48, 1267–1281 (2008).
- Joshi A , BauerR, KueblerPet al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J. Clin. Pharmacol. 46, 10–20 (2006).